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In the past few years, plant biotechnologyhas gone beyond traditional agriculturalproduction of food, feed and fibre, and
moved to address more complex contemporary
health, social and industrial challenges. The
new era involves production of novel pharma-
ceutical products, speciality and fine chemi-
cals, phytoremediation and production of
renewable energy resources to replace non-
renewable fossil fuels. Plants have been
shown to provide a genuine and low-cost
alternative production system for high-value
products. Currently, the principal plant-made
products include antibodies, feed additives,
vaccine antigens and hormones for human
and animal health, and industrial proteins.
Despite the unique advantages of scalability,
cost and product safety, issues of politics,
environmental impact, regulation and socio-
economics still limit the adoption of bio-
pharmaceuticals, especially in the developing
world. Plant-based production systems have
further complicated biosafety, gene flow and
environmental impact assessments with
generally genetically modified plants, topics
that are already partially understood. This
article provides a background to biopharming,
highlighting basic considerations for risk
assessment and regulation in developing
countries, with an emphasis on plant-based
vaccine production in South Africa.
Introduction
Molecular plant biotechnology, and
genetic engineering in particular, have
been around for some time now, and can
be said to be mature technologies. To date,
the rate of adoption of crop biotechnology
has been remarkable with a worldwide
increase in hectarage of genetically modi-
fied (GM) crops from a few thousand in
1996 to more than 90 million in 2005.1
Herbicide tolerance and insect resistance
were the major traits adopted for single,
double or triple gene stacking in soya
beans, cotton, canola or maize, with a con-
comitant improvement in farmers’ profit
margins and lives. Despite the uncertainty
and controversy in Europe and Africa in
the past decade with respect to agricultural
biotechnology, recent years have seen a
policy shift in countries such Spain,
Portugal, Germany and South Africa
towards GM crops.1 Lately, biotechnol-
ogy has gone beyond traditional agricul-
tural products (feed, fibre) to address
more complex health-related, social and
industrial challenges. The new era involves
production of novel pharmaceutical
products such as vaccines,2 speciality and
fine chemicals, phytoremediation3–5 and
production of renewable energy resources
to replace non-renewable fossil fuels.1
Unfortunately, these novel ideas and
endeavours have brought further com-
plexity to the only partially understood
fields of biosafety and environmental
impact assessments of GM plants, topics
that will be addressed in this article. We
also provide a background to biopharming,
highlighting basic considerations for risk
assessment and regulation in developing
countries, with a bias towards vaccine
production in plants in South Africa.
The need to find alternative methods to
complement microbial and mammalian
systems in the production of high-value
products such as drugs, enzymes, and
antibodies6 has recently given birth to the
concept of ‘biopharming’, or plant-based
pharmaceuticals (PBP). The biopharming
industry is projected to be worth $100
billion by the year 2020 (www.molecular-
farming.com). Currently, the main prod-
ucts that have been expressed in plants
include antibodies, feed additives, vaccine
antigens and hormones for human and
animal health and industrial proteins.7–9
Of particular importance has been the
development of PBP to find cures or
treatments for the so-called ‘orphan dis-
eases’ including TB, malaria, typhoid and
cholera. These are undoubtedly major
killers in the developing countries of
sub-Saharan Africa, in addition to the
ubiquitous and deadly HIV/AIDS.
Why choose plants to produce
vaccines?
According to the World Summit on
Children, an ideal vaccine should have
the following characteristics: it should be
administrable as a single dose, preferably
orally; be effective when given near birth;
be heat stable; comprise multiple antigens;
be effective against diseases which are not
current targets; and most importantly, it
should be affordable.10 Several alternative
production systems including plant-
based vaccines (PBV) are being tested in
order to produce these ideal vaccines. To
this end, vaccine antigens for a wide
range of diseases involving HIV, hepatitis
B virus and human papillomaviruses
(HPVs) have been effectively expressed
in plants.11 Interestingly, these antigens
apparently fold correctly and assemble
into quaternary structures similar to
those seen in mammalian tissues, are also
glycosylated where appropriate, and are
highly immunogenic. This contrasts with
microbial systems which are unable to
simulate the post-transcriptional modifi-
cation of mammalian cells, and are either
unable (if bacteria) properly to glycosylate,
or even over-glycosylate the proteins
(if yeasts). In addition, indications are
that plant-based vaccines might best be
administered orally either as only partially
purified preparations or even in their raw
form, with the plant tissue providing a
natural bioencapsulation, thus eliminating
the costs and risks of injection and needles.
Research into the best delivery systems
for PBVs is still in its infancy. However,
using appropriate plant expression organs
such as seeds combined with artificial and
conventional preservation methods such
as air and freeze drying, proteins can be
stabilized at room temperature for a long
time: this allows increasing vaccine cover-
age where there is no refrigeration. Because
of the relative ease of scalability, the
production costs of PBV are estimated to
be reduced from $1000–5000 per gram of
protein for animal systems to $1–10 in
plants,11 and about 10-fold less when
compared to microbial fermentation
production costs.12 For developing coun-
tries, this significant cost saving can be
used to meet other needs such as im-
provement of infrastructure for health
care delivery and hunger alleviation.
Bacterial products almost invariably
come contaminated with endotoxins,
necessitating meticulous purification,
which increases the cost of goods. Finally,
PBVs are very safe because they are sub-
unit vaccines made of non-replicating
components, and additionally have no
risk of viral or other human-transmissible
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contamination as can occur with mamma-
lian cell culture products.
Although some ‘big Pharma’ companies
have been sceptical of this technology,
relatively huge investments have been
made in the industry: for example, Bayer
CropScience recently acquired ICON
Genetics and Dow AgroSciences is licens-
ing a Newcastle disease virus vaccine for
chickens, the first livestock vaccine made
commercially, thus increasing competition
in the industry. Having said that, it is
apparent Africa might not benefit from
this new technology unless proper foun-
dations in the form of policies for research
and development, regulation and the
relevant infrastructure for growing PBVs
are put in place.
Production systems
There is an array of plant production
technologies that have been successfully
used or are being developed for bio-
pharming: they include transient expres-
sion (using viral vectors, agroinfiltration,
and cell or tissue culture)13–16 and stable
transformants (transgenic plants for in
planta accumulation17 or secretion through
roots or leaves, as well as transplastomic
plants in which genes for the target prod-
uct are integrated into the chloroplast
genome).18,19
Until recently, transient somatic expres-
sion through agroinfiltration — or the
infiltration of plants with suspensions of
recombinant Agrobacterium tumefaciens —
was generally used to verify transformation
of the gene expression vector (construct)
activity and to validate small amounts of
recombinant proteins.20,21 However, it is
now considered a bona fide protein expres-
sion strategy in its own right, that can
yield large amounts of protein.14 Agro-
infiltration has been scaled-up with the
help of post-transcriptional gene silencing
suppressors such as the plant virus-derived
p19 and NSs,15 to produce commercial
yields as high as 100 mg of protein per
kilogram of tobacco processed on a
weekly basis.22 In this case the recombinant
protein is recovered within a short time
with minimum cost. On the other hand,
viral vectors have been reported to pro-
duce high protein yields in a short time
and to allow for mixed infections, but
there are safety concerns and construct
limitations associated with this approach.
The main limitation of transient expression
is variability in protein yields among and
between batches, and the potentially
higher cost of production compared to
transgenic production.
Stable transformation systems are
based on the incorporation of the foreign
genetic material into the plant nuclear or
plastid genome, generating transgenic
plants. Several methods for transgene
delivery have been developed over the
years including Agrobacterium-mediated
transformation, microprojectile bombard-
ment, electroporation and microinjection.23
The transgene is expressed in the whole
plant, specific organ or cell lines over
generations, allowing ease of scaling-up
and purification. It has become clear,
however, that protein expression in the
plant cell cytosol often results in low
expression and gene silencing. As a solu-
tion, transit peptides are used to target
nuclear encoded proteins into different
subcellular compartment such as the plas-
tids (chloroplasts, etioplasts and chromo-
plasts), endoplasmic reticulum, oil and
protein bodies, vacuole and apoplast.24,25
A variation on this concept is the direct
incorporation of the transgene into the
chloroplast to form transplastomic trans-
genic lines.26 Transplastomics have several
advantages including high expression
levels that can be achieved for nuclear
encoded proteins because transgene copy
number is high as a result of the many
chloroplasts in a typical photosynthetic
cell. Furthermore, there is no gene silenc-
ing; and multiple genes can be expressed
in operons as the chloroplast mechanism
is basically prokaryotic, and gene silencing
is a eukaryotic phenomenon. Of particular
significance is the maternal inheritance of
chloroplasts in all higher angiosperms,
which helps in transgene containment22
as transgenes are not transmitted via
pollen. However, this system has many
of the same drawbacks as prokaryotic
expression, including lack of glycosyla-
tion and incorrect folding of certain
proteins.
Although whole plant systems are the
most widely used, cell cultures and ‘hairy
root’ cultures have emerged as recent
favourites for the expression of small
molecules. With these systems the protein
can be either harvested from the tissues
directly or from the liquid media after
deposition through root exudation or
apoplastic plant pathways using the
KDEL endoplasmic reticulum targeting
sequence. Moreover, comparative target-
ing experiments have shown that the
secretory pathway via the endoplasmic
reticulum may produce a 2–10-fold in-
crease in protein yields compared to accu-
mulation in the cytoplasm. This may be
explained by the proper oxidation envi-
ronment, fewer proteases, and abundant
molecular chaperons helping to achieve
proper protein folding and stability.27
In summary, a broad range of technology
and plant host and species have been
developed for the expression of
plant-made biopharmaceuticals. The type
of product and crop species are the princi-
pal factors influencing the choice of a par-
ticular system, as will be discussed below.
Issues in the production of PBP
Despite being one of the most exciting
biological innovations of our times, there
are numerous obstacles to the successful
exploitation of biopharmaceuticals, espe-
cially in the developing world. As a result
of political, environmental, regulatory
and socio-economic issues coupled with
pressure from organized environmental
non-governmental organizations, or
‘greens’ as they are commonly called,
Africa may miss out on beneficial technol-
ogies that could change lives for the
better. Until and unless these concerns are
properly and decisively addressed, bio-
pharmaceuticals likewise will never be
locally produced in Africa, and may never
reach the people who need them the
most. However, inadequate scientific
understanding of the effects of some GM
technologies has led to a precautionary
approach by most governments of both
rich and poor nations. Developing coun-
tries, especially in Africa, are susceptible
to raw, untested and potentially dangerous
technologies from industrial states, and
perhaps rightfully tend to protect them-
selves by putting in place the necessary
controls and seek to gain relevant experi-
ence before committing themselves to
such technologies as biopharming. Some
of the issues underpinning the controls,
checks and balances are summarized
below.
Environmental considerations
Despite the intensive research into the
ecological impact of GM plants around
the world, our knowledge and under-
standing is still inadequate.28,29 There is a
fine line dividing the net benefits and
environmental risks as clearly demon-
strated by the conflicting reports from the
different studies on the subject.30 Conse-
quently, there is immense distrust and
doubt among consumers about even
some basic scientific facts on GM products.
Although most of the concerns are genuine
and scientifically sound, some seem to be
fruits of consistent misinformation and
bad publicity via the media. Nonetheless,
the need to address these concerns
cannot be overemphasized. The principal
environmental risks include detrimental
effects on non-target organisms, gene
flow to wild relatives or non-transgenic
varieties, the inadvertent creation of
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weeds, development of resistance to
pesticides and tolerance of traditional
pathogens, production of novel toxins,
recombination of bacteria or viruses to
produce new pathogens, impact on agro-
biodiversity and crop genetic diversity
(see McGeoch and Pringle31 for refer-
ences). Studies have been conducted in
other countries to understand and adopt
mitigation strategies to address these
risks but the outcomes may not be easily
transferable because of the unique cli-
mate and agroecosystems of South Africa
and Africa at large. This further strength-
ens the urgent need for vigorous risk
assessments and local interventions.
In short, the possibility of transgene
introgression into non-modified counter-
parts,32 volunteer plants that may become
weedy nuisances, and identity preserva-
tion, among others are the main concerns
that have led to justifiable attacks on the
adequacy of the current frameworks for
environmental risk assessment and moni-
toring. For example, contradictory reports
of transgene flow from GM to non-GM
maize in Mexico31,33 have recently fuelled
public fears of the technology. Moreover,
the recent case where ProdiGene Inc. in
the US was fined $3.25 million after their
GM corn, which expresses a drug for pig
diarrhoea, was discovered in a soybean
field has had serious knock-on effects,
including discussion of a moratorium on
using crop plants for the expression of
biopharmaceuticals. Serious questions
could be asked in the light of this scandal,
such as whether the GM maize volunteer
plants could have been discovered in a
non-GM maize field. Although our un-
derstanding of pollen dispersal and pollen
viability has improved over the years,
climate change and the effects of strong
winds and hurricanes are an additional
complicating factor; we need to deal with
the various elements of the problem
separately. For example, issues of the safe
isolation distances between GM and
non-GM crops and the allowable threshold
of volunteer plants need to be re-visited.
In an ideal situation the use of non-food
or non-feed crops would be preferred.
However, food crops have well-developed
transformation protocols, low-cost pro-
duction and processing and reduced toxi-
cants22 such that they remain favourite
choices for biopharming.34
Within the African context, however,
other factors such as human migration
and illegal seed imports, particularly
involving both food and medicinal plants,
are more serious challenges for African
governments. This is illustrated by the
fact that, on average, 1000 to 2000 illegal
Zimbabwean immigrants were deported
weekly from South Africa in the year 2005
alone, with a presumably higher unde-
tected quotient.35 To our knowledge, no
studies have been commissioned to assess
the risk posed by these migrants in terms
of the illegal movement of seed. This is
a clear indication of the lax and poorly
enforced phytosanitary regimes in African
countries. It is therefore imperative that
the anthropogenic factor be incorporated
in risk assessment for PBP. The issues
raised above are but a few to highlight
the need for serious environmental risk
assessments for biopharmaceuticals.
Regulatory and legal issues
The GMO debate in Europe and recent
advances in science have made regulation
of biopharmaceuticals more complex
than ever. On the one hand, regulatory
bodies have been confronted with the
dilemma of balancing sound scientific
principles against public fears. On the
other hand, science has not unequivo-
cally declared biotechnologies either safe
or unsafe in many cases nor even the
conditions in which either suffices. This
has caused unnecessary rejection of
some useful technologies and delays in
producing a regulatory framework for
biopharmaceuticals. Nevertheless, there
have been two interesting developments
in the past three years. First, scientists are
beginning to understand better the dynam-
ics of transgene flow in both domestic and
wild ecosystems,36–39 as well as the mecha-
nisms of insect and weed resistance.40,41
This has helped in making science-based
decisions in terms of risk assessment and
management. Second, the US Food and
Drug Administration (FDA)42 and Euro-
pean Agency for the Evaluation of Medic-
inal Products43 have produced guidelines
highlighting specific considerations for
producing biopharmaceuticals. These
developments are a step in the right direc-
tion, but more are still needed, especially
from developing countries, in order to
harmonize the respective regulatory
bodies with those mentioned above. Most
governments are in the process of pro-
ducing, or have just produced, legislation
to govern the introduction GMOs, and
the respective regulatory bodies have
still to survive the test of time and public
pressure. For instance, countries like
Zimbabwe have a well-developed and
comprehensive biotechnology regulatory
framework but no GM products have
reached the market. The main challenge
at government level is to harmonize
legislation governing biopharmaceuticals.
For example, the Federal Plant Pest Act,
Federal Food, Drug and Cosmetic Act,
Federal Insecticide, Fungicide and
Rodenticide Act and the Toxic Substances
Control Act in the United States govern
biopharmaceutical product development.
The successful adoption of biopharma-
ceuticals in Africa may be hampered by
the complex legal issues that need to be
addressed such as patent protection of
intellectual property rights (IP) and licens-
ing of patented technology to provide
freedom to operate.44 A progressive policy
for rich countries would be to make IP
available to developing countries on
humanitarian grounds.2 Whether patent
protection benefits the developing world
or not is debatable. When developing
countries might use others’ IP with mini-
mum costs, there is a danger of killing
knowledge creation and innovation by
promoting copying and imitation.45 A
summary of the important regulatory
considerations presented by the FDA as
they affect Africa is discussed below.
Choice of host plant
The choice of crop in which the pharma-
ceuticals are produced has critical implica-
tions for the environment. As mentioned
above, the use of openly pollinating crop
species raises particular concerns about
pollen dispersal. Then there is the issue of
food versus non-food crops. Basically, the
choice of the production platform should
be based on the potential allergenicity or
toxicity of the molecules being expressed,
the method of propagation, and measures
of confinement to ensure no inadvertent
mixing of bioengineered plant material
with human food or animal feed. Any
chosen host plant has to be properly
described to include growth habit, timing
of harvest, and storage. In this respect
several plant hosts have been used,
including tobacco, maize, alfalfa, rice and
tomato.46 Among the leafy plants, tobacco
has been widely used, mainly because it is
easy to transform and regulation of
transgene expression is well-understood.
Being a non-food, non-feed crop, tobacco
reduces the risk of contaminating the
food or feed chain. The often high nicotine
and toxic alkaloids contents may necessi-
tate meticulous purification, reducing the
attractiveness of tobacco as a host plant.
However, the developed world’s growing
opposition to smoking, coupled with the
well-established agronomic conditions in
Africa for the crop, leaves tobacco as the
most suitable African candidate for bio-
pharmaceutical production. Its potential
is apparent in results from our laboratory,
which has recorded protein yields as high
as 800 mg per kg (12–17% total soluble
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protein) of HPV-16 L1 antigen in trans-
genic tobacco (J. McLean et al. unpub-
lished work). With a yield of up to 2
tonnes per hectare it is possible that a few
small tobacco farms could produce
enough vaccines for the whole of Africa.
On the other hand, cereals such as
maize would be difficult to contain because
of the possibility of the escape of trans-
genic material via pollen dispersal and
volunteer plants. These problems are
confounded by the fact that maize is the
staple food for most of southern and
central Africa, making the production of
pharmaceuticals in this crop an emotive
issue. Having said that, responsibility
should be well-defined at all stages of
production, harvesting, and transport,
with all products being properly labelled.
Traceable documentation of the whole
production process, quantitative data
characterizing the distribution of product
in different plant tissues (leaves, roots,
stalks and seeds), recombinant DNA
vectors and seedbanks should be kept.
Extraction and processing should enable
efficient concentration of the active
compound and separation from the rest
of the bulky plant material with minimum
concentration of contaminants. Most
importantly, all processing procedures
should be properly validated and equip-
ment sterilized to the highest standards
expected for good manufacturing practice.
Moreover, purification processes need to
demonstrate the extent of lot-to-lot varia-
tion in product yield, and to show suffi-
cient removal of contaminants to provide
a consistent product. It would be difficult
to satisfy this requirement, however,
when using whole plant systems such as
field-grown transgenic plants, because of
inherent genetic differences and variability
in edaphic conditions.
Waste material
According to the FDA guidelines, all
in-process wastes (by-products of column
wash and diafiltration solutions, for exam-
ple), rejected material and residual source
matter from the purification process
should be treated to inactivate the regu-
lated product prior to disposal in a safe
and appropriate way. Disposal of this
matter should be carried out in a manner
to ensure that the product does not enter
the human food or animal feed chain.
Both primary disposal and secondary use
of the material should be approved and
well-documented. Interestingly, poor
waste management is one of the main
challenges of even relatively rich African
nations, as witnessed by the high inci-
dence of cholera, E. coli infection and
typhoid in South Africa,47 mainly from
municipal sewage. One could therefore
be justified in concluding that there is no
guarantee that waste from biopharma-
ceuticals will not end up in drinking
water. Of greater concern, though, would
be the remediation of the problem when it
arises.
The way forward
According to Leshner,48 the success of
biotechnology in developing countries
depends on adequate scientific and tech-
nological cooperation supported by
well-developed infrastructure to sustain
the science and its progress. With that in
mind, proper regulation and enforcement
should form the core of the quest for the
success of biopharming. Two related
strategies can be used to mitigate the risks
of the technology: these are confinement
and containment.21 Confinement refers to
biological isolation of the plant using
techniques involving, for example, buffer
zones, cytoplasmic male sterility, trans-
plastomics, self-pollinating species and
regulated promoters.49 On the other
hand, containment is the physical isola-
tion of the plant in indoor secure facilities
like greenhouses, the maintenance of
isolation distance and secretion systems.
To this end, the product can be collected
in root exudates in hydroponic cultivation,
thus minimizing the accidental release of
genetically modified organisms expressing
antigens or antibodies into the environ-
ment. It must be emphasized that identifi-
cation, assessment and containment/
mitigation of biohazards can be achieved
only within a strongly enforced, stringent
environmental regulatory framework.50
The potential benefits of biopharming
are enormous but they can be realized
only with good policy, exhaustive risk
assessments and, most importantly, com-
pliance with management specifications
and monitoring of such compliance.
Moreover, public education and the
broad dissemination of information on
GM technology in general should be
made a priority so as to raise awareness of
the separate risks and provide an informed
basis for acceptance or rejection of these
technologies. The solutions to the issues
raised in this article should help to achieve
the safety and purity of the products.42
This article is based on a presentation given at the
‘GMO risk assessments and triggers for environmen-
tal impact assessment’ workshop, 1–2 November
2005, in Pretoria.
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African Natural History
This new research journal was launched in
November 2005 by Iziko Museums of Cape
Town. In part to take the place of the Annals
of the South African Museum, the publishers
intend to produce a single volume annually,
the second of which will appear towards
the end of this year.
African Natural History publishes papers
on the natural history of Africa, with partic
ular emphasis on research related to sys
tematics, biodiversity, zoology, geology
and palaeontology. Authors are invited to
submit articles for consideration covering
these fields of investigation: preference will
be given to research that includes the study
of specimens housed in Iziko collections
but does not exclude work based on other
material.
Instructions to authors can be found on
Iziko’s home page at
www.iziko.org.za/nh/publications/index.htm
The editor can be contacted at
African Natural History, Natural History
Collections Division, Iziko South African
Museum, P.O. Box 61, Cape Town 8000,
South Africa
E-mail: hklinger@iziko.org.za
Write for popular quarterly science magazine
QUEST: Science for South Africa
The Academy of Science of South Africa’s popular general interest science magazine, QUEST:
Science for South Africa, continues to publicize the findings and achievements of the country's
researchers. In it, scientists tell fellow South Africans about the science being conducted here in
a way that makes the information accessible to the general public, to schoolgoers, and to those
across the range of higher education institutions.
CALL FOR CONTRIBUTIONS: QUEST welcomes contributions from scientists, researchers,
educators, and other professionals with appropriate knowledge and expertise. It offers oppor-
tunities to tell the general public about the best and newest research being done in South
Africa, and about the contribution of science and technology to our growth and our future.
For details, please contact the editor, Elisabeth Lickindorf, at
P.O. Box 1011, Melville 2109, South Africa, or by
e-mail at editor.quest@iafrica.com
(include the phrase "Quest query" or "Quest contribution" in the subject line).
FOR COPIES AND SUBSCRIPTIONS contact
Quest Subscriptions at
P.O. Box 1011, Melville 2109, or by
e-mail at editor.quest@iafrica.com
(include the phrase "Quest Subscription" in the subject line).
Tel./Fax: (011) 673 3683.
